Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 30 publications
Erratum: Safety, Tolerability, and Antitumor Activity of Zipalertinib Among Patients With Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertions.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 14, 2026
Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor-2 Rearrangement: Results From the Phase III FIGHT-302 Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 01, 2026
Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor-2 Rearrangement: Results From the Phase 3 FIGHT-302 Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 01, 2026
First-in-Human Phase I/II Study of INCAGN01876, a Glucocorticoid-Induced Tumor Necrosis Factor Receptor Agonist, in Patients with Advanced or Metastatic Solid Tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: December 19, 2024
First-in-human phase I open-label study of the LAG-3 antagonist antibody INCAGN02385 in patients with select advanced or metastatic solid tumors.
Journal: The oncologist
Published: November 06, 2024
First-in-human phase I open-label study of the anti-TIM-3 monoclonal antibody INCAGN02390 in patients with select advanced or metastatic solid tumors.
Journal: The oncologist
Published: November 06, 2024
Safety, Tolerability, and Antitumor Activity of Zipalertinib Among Patients With Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertions.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 29, 2023
First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors.
Journal: Journal for immunotherapy of cancer
Published: July 11, 2022
Sequential therapy with INCAGN01949 followed by ipilimumab and nivolumab in two patients with advanced ovarian carcinoma.
Journal: Gynecologic oncology reports
Published: July 27, 2020
PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance.
Journal: Nature immunology
Published: April 01, 2019
Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors.
Journal: Journal for immunotherapy of cancer
Published: February 15, 2018
Last Updated: 09/26/2026